List of works - Naomi P. Visanji

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease

scientific article published on February 2017

Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers

scientific article published on 01 January 2018

Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats

scientific article published on 30 June 2006

Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker

scientific article published on 26 December 2013

Author response

scientific article published in September 2015

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities

scientific article published on 04 September 2019

Chronic pre-treatment with nicotine enhances nicotine-evoked striatal dopamine release and alpha6 and beta3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat.

scientific article

Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.

scientific article published on 17 April 2018

Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease

scientific article

Dendritic spine density is altered in a mouse model of Cockayne syndrome.

scientific article published in June 2013

Dietary resveratrol administration increases MnSOD expression and activity in mouse brain.

scientific article published on 16 May 2008

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

scientific article

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

scientific article published in September 2006

Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.

scientific article published on 17 August 2011

Gastrointestinal dysfunction in Parkinson's disease

scientific article published on 01 June 2015

Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease

scientific article published on 10 January 2017

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

scientific article published in June 2006

Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology

scientific article published on 14 May 2020

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

scientific article published on July 2010

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease

scientific article published on 14 March 2012

Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease

scientific article published on 23 August 2019

Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson’s Disease

scientific article published on 01 January 2018

Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy.

scientific article published in January 2013

Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies

scientific article published on 10 November 2017

Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

scientific article published in January 2010

Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia

scientific article

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

scientific article

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

scientific article published on 01 November 2006

Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.

scientific article published in April 2008

Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease

scientific article published on 14 May 2018

Reply to: Gray et al

scientific article published on 12 June 2014

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease

scientific article published on 01 June 2018

Synchrotron XRF imaging of Alzheimer's disease basal ganglia reveals linear dependence of high-field magnetic resonance microscopy on tissue iron concentration

scientific article published on 06 March 2019

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

scientific article

The prion hypothesis in Parkinson's disease: Braak to the future

scientific article

The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

scientific article

Tumor Necrosis Factor-α Underlies Loss of Cortical Dendritic Spine Density in a Mouse Model of Congestive Heart Failure

scientific article

Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease

scientific article published on 20 November 2020

α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity.

scientific article published on 23 January 2013

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

scientific article published on 21 October 2016

List of works by Naomi P. Visanji

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease

Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers

Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats

Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker

Author response

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities

Chronic pre-treatment with nicotine enhances nicotine-evoked striatal dopamine release and alpha6 and beta3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat.

Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.

Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease

Dendritic spine density is altered in a mouse model of Cockayne syndrome.

Dietary resveratrol administration increases MnSOD expression and activity in mouse brain.

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.

Gastrointestinal dysfunction in Parkinson's disease

Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease

Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease

Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson’s Disease

Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy.

Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies

Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.

Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease

Reply to: Gray et al

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease

Synchrotron XRF imaging of Alzheimer's disease basal ganglia reveals linear dependence of high-field magnetic resonance microscopy on tissue iron concentration

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

The prion hypothesis in Parkinson's disease: Braak to the future

The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

Tumor Necrosis Factor-α Underlies Loss of Cortical Dendritic Spine Density in a Mouse Model of Congestive Heart Failure

Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease

α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.